Full Press Release Details
Summit Therapeutics plc
( Summit or the Company )
DIRECTOR SHARE DEALING
2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Company has been notified that Mr
David Wurzer, Non-Executive Director of the Company, has on 18 June 2015 bought 1,500 American Depositary Shares ( ADSs ) of Summit at a price of $11.65 per ADS.
Following this notification Mr Wurzer s beneficial interest in Summit Shares is 1,500 ADSs (equivalent to 7,500 ordinary shares on 1p nominal value),
representing approximately 0.01% of the Company s current issued share capital.
The ADSs were acquired on the NASDAQ Global Market. This
notification relates to disclosures made in accordance with Rule 17 Schedule 5 of the AIM Rules.
For more information, please contact:
| Summit Therapeutics | ||||
| Richard Pye (UK office) | Tel: | +44 (0)1235 443 951 | ||
| Erik Ostrowski (US office) | +1 617 294 6607 | |||
| Cairn Financial Advisers LLP | ||||
| (Nominated Adviser) | ||||
| Liam Murray / Tony Rawlinson | Tel: | +44 (0)20 7148 7900 |